Senolytics: First Human Trial Confirms Reduction in Frailty Markers
Original title: Senolíticos: primer ensayo humano con dasatinib + quercetina reduce marcadores de fragilidad
A phase 2 trial from Mayo Clinic has demonstrated that the combination of dasatinib and quercetin significantly reduces senescent cell burden in older adults with frailty, improving their physical function within three months. This finding marks the first concrete clinical result of a strategy aging biology has pursued for years: selectively eliminating the damaged cells that accumulate with age and drive chronic inflammation. The magnitude of improvement in frailty markers opens an unexpected door for pharmacological interventions in the functional decline linked to cellular senescence, transforming laboratory observation into actionable therapeutic option.
Editorial summary by LongevityMap. For the full article and references, visit EBioMedicine.